Immunophenotypic characteristics of ZNF384 rearrangement compared with BCR‐ABL1, KMT2A rearrangement, and other adult B‐cell precursor acute lymphoblastic leukemia

Background ZNF384 rearrangement has been recently identified as a new subtype of B‐cell precursor acute lymphoblastic leukemia (BCP‐ALL). However, comprehensive studies clarifying immunophenotypic features and discriminating them from non‐ZNF384 in adult BCP‐ALL remain scarce to date. Methods Flow c...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cytometry. Part B, Clinical cytometry Clinical cytometry, 2022-09, Vol.102 (5), p.360-369
Hauptverfasser: Wang, Ya‐Zhe, Qin, Ya‐Zhen, Chang, Yan, Yuan, Xiao‐Ying, Chen, Wen‐Min, He, Ling‐Ling, Hao, Le, Shi, Wei‐Hua, Jiang, Qian, Jiang, Hao, Huang, Xiao‐Jun, Liu, Yan‐Rong
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background ZNF384 rearrangement has been recently identified as a new subtype of B‐cell precursor acute lymphoblastic leukemia (BCP‐ALL). However, comprehensive studies clarifying immunophenotypic features and discriminating them from non‐ZNF384 in adult BCP‐ALL remain scarce to date. Methods Flow cytometric assessments were retrospectively performed in 43 patients with ZNF384 rearrangement, 45 with BCR‐ABL1, 29 with KMT2A rearrangement and 44 with other BCP‐ALL in the analysis cohort. Results CD33‐ and CD13‐positive frequencies were significantly higher in patients with ZNF384 rearrangement than in those with non‐ZNF384; however, no significant difference was observed in CD10‐ and CD123‐positive frequencies. Analysis of antigen‐positive cell proportion and median fluorescence intensity (MFI) further indicated that patients with ZNF384 rearrangement had significantly lower CD10 and higher CD33, CD13, and CD123 proportion and MFI. However, compared with KMT2A rearrangement, the CD10 expression in patients with ZNF384 rearrangement was higher, with the median percentage and MFI of 36.16 (3.63–94.79)% versus 4.53 (0.03–21.00)%, and 4.50 (0.86–32.26) versus 2.06 (0.87–4.04), respectively (p 
ISSN:1552-4949
1552-4957
DOI:10.1002/cyto.b.22086